Based on a web panel discussion presented by ShareVault in association with BIO, LES and Pullan Consulting
Often biotech companies seeking to out-license or in-license a drug candidate or other asset, or otherwise partner with another biopharmaceutical company are unfamiliar with the due diligence process.
To avoid costly mistakes and recognize potential problems, biotech licensing and pharmaceutical business development consultant Linda Pullan invited six experts in the field of biopharma partnering due diligence to sit down and discuss best practices for conducting due diligence that results in successful long-term partnerships.
Download the 'Nuts & Bolts of Due Diligence in Biopharma Partnering' to learn:
Biotech and Money is an influential community of senior life science decision makers. Through our impactful events, powerful thought leadership content and unique networking opportunities, we exist to forge a fundamentally better way to promote and facilitate investment, financing, partnerships and deal making in healthcare